scispace - formally typeset
X

Xiaoliang Xu

Researcher at Nanjing University

Publications -  24
Citations -  522

Xiaoliang Xu is an academic researcher from Nanjing University. The author has contributed to research in topics: Medicine & Hepatocellular carcinoma. The author has an hindex of 9, co-authored 17 publications receiving 314 citations. Previous affiliations of Xiaoliang Xu include Southeast University & Nanjing Medical University.

Papers
More filters
Journal ArticleDOI

Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC.

TL;DR: It is shown that Lnc-Tim3 is upregulated and negatively correlates with IFN-γ and IL-2 production in tumor-infiltrating CD8 T cells of HCC patients, suggesting that LngRNA and its associated signaling pathways may influence the outcome of cancer therapies aimed at modulating the acquired immune system.
Journal ArticleDOI

Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma.

TL;DR: The results suggest that DGCR5 may be a participator in HCC and can serve as potential biomarker for the diagnosis and prognosis in H CC.
Journal ArticleDOI

CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein-Coupled Receptor-Mediated Signaling in Hepatocellular Carcinoma.

TL;DR: The utility of CD97 as an effective potential prognosticator and therapeutic target for HCC is supported and integrated regulatory interactions between CD97 and GRK6 stimulated downstream matrix metalloproteinase 2/9 secretion and, consequently, HCC metastasis.
Journal ArticleDOI

Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma.

TL;DR: The epigenetic interaction between Linc00441 and bidirectional transcripted neighbor RB1 may be a de novo theory cutting-point for the inactivation of RB1 in HCC and may serve as targeting site for tumor therapy in the future.
Journal ArticleDOI

The long non-coding RNA Linc-GALH promotes hepatocellular carcinoma metastasis via epigenetically regulating Gankyrin.

TL;DR: Mechanistically, Linc-GALH could regulate the expression of Gankyrin through controlling the methylation status of Ganksyrin by adjusting the ubiquitination status of DNMT1 in HCC, and this work demonstrated the role and functional mechanism of Linc, and indicated that Linc may act as a prognostic biomarker and potential therapeutic target for HCC.